Roche Diagnostics Operations, Inc.

Roche Diabetes Care, Inc.

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Michael Tacke

Markus Roessler

Johann Karl

Dieter Heindl

Wolfgang Rollinger

Julia Riedlinger

Marie-Luise Hagmann

Michael Schraeml

Michael Gerg

Herbert Andres

Thomas Meier

Hartmut Duefel

Theresa Kott

Christian Klein

Wolfgang Schaefer

Alfred Mertens

Alfred Engel

Gerhard Niederfellner

Christa Hubner-Parajsz

Ulrich Schwaneberg

Werner Zolg

Peter Berndt

Beatus Ofenloch-Hahnle

Jarema Peter Kochan

Volker Schmid

Friedemann Krause

Monika Soukupova

Norbert Wild

Hanno Langen

Hemanshu Mundhada

Stefan Palme

Susanne Schmolke

Ursula Garczarek

Marie Luise Hagmann

Liliana Mantovani-Endl

Ingo Lindner

Michael Thierolf

Erik Uwe Arango Gutierrez

Marco Bocola

Hartmut Düfel

Hartmut Dufel

Jan Van Dieck

Julia Kloeckner

Christoph Rutz

Claudio Sustmann

Michael Pfeffer

Andrea Geistanger

Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

Detection of a posttranslationally modified polypeptide by a bivalent binding agent

The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

ASC as a marker for lung cancer

Novel glucose oxidase (GOx) variants are disclosed that have the substitutions of T30V and I94V set forth in SEQ ID NO:1, and additionally at least one further amino acid substitution in the enzyme sequence in any of the positions S53; A137; A173; A332; F414 and V560. The GOx variants herein exhibit specificity for glucose and significantly reduced oxygen consumption rates and/or increased enzyme activity for electron mediators other than oxygen. Also provided are assay devices incorporating at least one of the GOx variants herein for improved blood glucose measurements.

Glucose oxidase variants and methods of using the same

Compositions, devices, kits and methods are disclosed for assaying glucose with a glycosylated, modified flavin adenine dinucleotide-dependent glucose dehydrogenase (FAD-GDH), variant thereof or an active fragment thereof, where at least one asparagine residue at positions N2, N168 and N346 of mature, wild-typeFAD-GDH according to SEQ ID NO:2 is substituted by one or more amino acids not suitable for glycosylation, thereby eliminating or inactivating, respectively, a potential glycosylation site at this position.

Glycosylated modified flavin adenine dinucleotide-dependent glucose dehydrogenases, compositions thereof as well as methods of making and using the same

Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Secernin-1 as a marker for cancer

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Method for providing diagnosis of cancer using seprase as a marker

The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

CYBP as a marker for lung cancer

Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

ARMET as a marker for cancer

Disclosed is a method aiding in the assessment of squamous cell carcinoma (SCC). It involves the use of the protein serpin B13 as a marker of SCC. Furthermore, the disclosure relates to a method for assessing lung cancer in a tissue sample derived from a patient having non-small cell lung carcinoma (NSCLC) and for differentiating SCC from adenocarcinoma or large cell carcinoma of the lung.

Serpin B 13 as a marker for squamous cell carcinoma of the lung

The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer

The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Nicotinamide N-methyltransferase as a marker for colorectal cancer

The present invention concerns an antibody against a hepatitis G virus antigen as well as a fragment of this antibody. The invention additionally concerns hybridoma cell lines as well as a conjugate that contains this antibody or the antibody fragment coupled to a biological molecule. Finally the present invention concerns the use of the antibody for the diagnostic detection of hepatitis G virus.

Antibodies against hepatitis G virus and their use for the diagnostic

Growing community of inventors

Munich, Germany

Michael Tacke